RVMD logo

Revolution Medicines Inc - Ordinary Shares (RVMD)

$162.69

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on RVMD

Market cap

$35.19B

EPS

-9.15

P/E ratio

--

Price to sales

--

Dividend yield

--

Beta

1.443657

Price on RVMD

Previous close

$166.87

Today's open

$166.78

Day's range

$161.69 - $167.99

52 week range

$67.27 - $224.31

Profile about RVMD

CEO

Mark A. Goldsmith

Employees

883

Headquarters

Redwood City, CA

Exchange

Nasdaq Global Select

Shares outstanding

216292323

Issue type

Common Stock

RVMD industries and sectors

Healthcare

Biotechnology & Life Sciences

News on RVMD

Revolution Medicines Wins EU Nod for Rasonque in Pancreatic Cancer

RVMD secures European Commission approval for Rasonque in metastatic pancreatic cancer, expanding its reach after a strong U.S. launch.

news source

Zacks Investment Research • Nov 17, 2026

news preview

Revolution Medicines, Inc. (RVMD) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Revolution Medicines, Inc. (RVMD) Presents at Jefferies Global Healthcare Conference 2026 Transcript

news source

Seeking Alpha • Nov 16, 2026

news preview

European Commission Approves Revolution Medicines' RASONQUE® (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer

REDWOOD CITY, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that the European Commission (EC) has approved RASONQUE (daraxonrasib) for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy.1 RASONQUE, given once daily as oral tablets, is approved for adults with metastatic pancreatic adenocarcinoma with or without an identified RAS tumor mutation.

news source

GlobeNewsWire • Nov 16, 2026

news preview

Revolution Medicines: RASONQUE Is Off To A Strong Start, But Expectations Are High

Revolution Medicines has transitioned to commercial operations with a strong initial RASONQUE launch, generating $197.6M in five weeks post-FDA approval. RASONQUE's early demand is validated by over 5,000 unique U.S. patients and broad reimbursement, but initial revenues include non-recurring factors and should not be annualized. RVMD's valuation is demanding at 63x forward sales, reflecting high expectations for RASONQUE's expansion and pipeline execution, leaving little room for operational missteps.

news source

Seeking Alpha • Nov 12, 2026

news preview

Revolution Medicines, Inc. (RVMD) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript

Revolution Medicines, Inc. ( RVMD ) 3rd Annual Guggenheim Healthcare Innovation Conference November 10, 2026 8:30 AM EST Company Participants Mark Goldsmith - CEO, President & Chairman Presentation Unknown Analyst Kick off this next discussion with Revolution Medicines. With me today, I have Mark Goldsmith, CEO.

news source

Seeking Alpha • Nov 10, 2026

news preview

Wall Street Analysts Think Revolution Medicines (RVMD) Could Surge 33.34%: Read This Before Placing a Bet

The consensus price target hints at a 33.3% upside potential for Revolution Medicines (RVMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

news source

Zacks Investment Research • Nov 10, 2026

news preview

Revolution Medicines' Pancreatic Cancer Drug Nearly Doubled Survival. Is the High-Flying Stock Still a Buy?

Its lead therapy is approved to treat previously treated patients with an advanced form of pancreatic cancer. The young drug company has a revolutionary pipeline of RAS-inhibitor therapies.

news source

The Motley Fool • Nov 8, 2026

news preview

Why Royalty Pharma Investors Could Be the Quiet Winners From Revolution Medicines' Groundbreaking Pancreatic Cancer Drug

Revolution Medicines' daraxonrasib has received FDA approval. Royalty Pharma estimates that the drug could produce peak revenues of $11 billion.

news source

The Motley Fool • Nov 8, 2026

news preview

What Revolution Medicines (RVMD) Said on Its Q3 Earnings Call

Revolution Medicines NASDAQ: RVMD reported $197.6 million in third-quarter net product revenue from its newly approved pancreatic cancer treatment RASONQUE, reflecting roughly five weeks of U.S. sales and treatment of more than 5,000 commercial patients.

news source

MarketBeat • Nov 5, 2026

news preview

Revolution Medicines Q3 Earnings: Stellar Company And Drug, But The Market Knows It

Revolution Medicines delivered $198M in Q3 revenue from RASONQUE's five-week U.S. launch, treating over 5,000 patients post-FDA approval. Despite strong early sales, RVMD's $40B valuation and high expectations temper further upside until sustained commercial traction or pivotal readouts materialize. RASONQUE's clinical data show clear superiority over chemotherapy in pancreatic cancer; expansion into NSCLC and other solid tumors underpins RVMD's multi-asset pipeline thesis.

news source

Seeking Alpha • Nov 5, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Revolution Medicines Inc - Ordinary Shares

Open an M1 investment account to buy and sell Revolution Medicines Inc - Ordinary Shares commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in RVMD on M1